121 related articles for article (PubMed ID: 15497327)
1. [Nuclear receptors--watchful mistrust of tamoxifen].
Dingermann T; Zündorf I
Pharm Unserer Zeit; 2004; 33(5):350-1. PubMed ID: 15497327
[No Abstract] [Full Text] [Related]
2. The science of selective estrogen receptor modulators: concept to clinical practice.
Jordan VC
Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
[No Abstract] [Full Text] [Related]
3. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
4. Biomedicine. Defining the "S" in SERMs.
Katzenellenbogen BS; Katzenellenbogen JA
Science; 2002 Mar; 295(5564):2380-1. PubMed ID: 11923515
[No Abstract] [Full Text] [Related]
5. Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer.
Ditzel HJ; Lyng MB
Nat Clin Pract Oncol; 2008 Jul; 5(7):376-7. PubMed ID: 18506164
[No Abstract] [Full Text] [Related]
6. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.
Sonpavde G; Okuno N; Weiss H; Yu J; Shen SS; Younes M; Jian W; Lerner SP; Smith CL
Urology; 2007 Jun; 69(6):1221-6. PubMed ID: 17572228
[TBL] [Abstract][Full Text] [Related]
7. Pak up your breast tumor--and grow!
Jordan VC
J Natl Cancer Inst; 2006 May; 98(10):657-9. PubMed ID: 16705113
[No Abstract] [Full Text] [Related]
8. Modification of tamoxifen response: what have we learned?
Lash TL; Ahern TP; Cronin-Fenton D; Garne JP; Hamilton-Dutoit S; Kvistgaard ME; Rosenberg CL; Silliman RA; Sørensen HT
J Clin Oncol; 2008 Apr; 26(10):1764-5; author reply 1765-6. PubMed ID: 18375910
[No Abstract] [Full Text] [Related]
9. Photodynamic cell-kill analysis of breast tumor cells with a tamoxifen-pyropheophorbide conjugate.
Fernandez Gacio A; Fernandez-Marcos C; Swamy N; Dunn D; Ray R
J Cell Biochem; 2006 Oct; 99(3):665-70. PubMed ID: 16795032
[TBL] [Abstract][Full Text] [Related]
10. [Hormone resistance and its modulation in breast cancer].
Kahán Z; Thurzó L
Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
[TBL] [Abstract][Full Text] [Related]
11. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
Terán Dávila J; Teppa Garrán AD
Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
[TBL] [Abstract][Full Text] [Related]
12. Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.
Teunissen SF; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
Anal Chim Acta; 2010 Dec; 683(1):21-37. PubMed ID: 21094378
[TBL] [Abstract][Full Text] [Related]
13. Resolution of menstrually related migraine following aggressive treatment for breast cancer.
Smitherman TA; Kolivas ED
Headache; 2010 Mar; 50(3):485-8. PubMed ID: 20039954
[TBL] [Abstract][Full Text] [Related]
14. Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?
Palmieri C; Gojis O; Rudraraju B; Cleator S
J Clin Oncol; 2008 Dec; 26(35):5824; author reply 5825-6. PubMed ID: 19001345
[No Abstract] [Full Text] [Related]
15. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
16. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Frasor J; Chang EC; Komm B; Lin CY; Vega VB; Liu ET; Miller LD; Smeds J; Bergh J; Katzenellenbogen BS
Cancer Res; 2006 Jul; 66(14):7334-40. PubMed ID: 16849584
[TBL] [Abstract][Full Text] [Related]
17. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
19. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
20. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
